ArticleJournal of medical virology2025
Reduced TLR3 and TLR9 Expression in Epidermodysplasia Verruciformis: Evidence From a Comparative Skin Study.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduced TLR3 and TLR9 Expression in Epidermodysplasia Verruciformis: Evidence From a Comparative Skin Study.Journal of medical virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by lifelong β-human papillomavirus (β-HPV) persistence, extensive flat warts, and increased risk of cutaneous squamous cell carcinoma. While TMC6, TMC8, and CIB1 mutations are recognized as genetic drivers, innate immune mechanisms contributing to HPV persistence remain incompletely defined. This study quantified the expression of Toll-like receptors (TLRs) 3, 4, 5, and 9 in normal skin and flat warts from patients with EV and immunocompetent individuals without EV (NEV). We performed immunohistochemical analysis on 135 formalin-fixed, paraffin-embedded specimens using standardized digital morphometry of epidermal keratinocytes. EV patients exhibited significantly reduced TLR3 and TLR9 expression in both normal skin and flat warts relative to controls, whereas TLR4 and TLR5 levels were comparable. Notably, flat warts from NEV individuals showed marked TLR3 upregulation relative to matched normal skin, whereas this response was absent in EV patients. These findings are consistent with an EV-associated epithelial innate-sensing phenotype. Our data suggest innate immune deficiencies may interact with previously described keratinocyte abnormalities, amplifying local immune dysfunction. These findings provide a framework for investigating TLR-based therapeutic approaches in EV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.